Let’s take a look at three reasons Medtronic’s stock could soar to new highs.
Medtronic rocked the health care world with the largest medical device acquisition in history, but this big buy is a huge step in the right direction for the world's largest pure device maker and its investors.
Renal denervation, the once-promising treatment for high blood pressure, has fizzled out after a failed trial from Medtronic.
JNJ's European approval for a renal denervation device was unexpected, but more work needs to be done.
Bard has significantly improved its growth outlook, but Wall Street seems a step or two ahead.
DexCom, Smith & Nephew, and Endo Health Solutions could be big health care stories this morning. Read on to find out why.
Hypertension treatment renal denervation has been a hot topic in the medical device industry, but a recent trial disappointment from Medtronic has companies like Covidien and Boston Scientific backpedaling.
Renal denervation's a huge opportunity for Medtronic, St. Jude Medical, and other leading device companies, but recent setbacks have investors wondering how long it will be before potential translates into results
A potential $3 billion/year therapy may not work nearly as well as hoped.
New technology that tracks blood sugar is driving sales and share higher at Dexcom.